Home › Therapeutic areas › Other biological preparations
Japan market screening · Therapeutic class
その他の生物学的製剤 · Japan Standard Commodity Classification
22 molecules in this class are marketed in Japan across 40 products. 1 of those products are not shipping normally today — 2.5% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Tocilizumabトシリズマブ（遺伝子組換え） | 5 | 1 | — | |
| Tocilizumab (Genetical Recombination) [Tocilizumab Biosimilar 1]トシリズマブ（遺伝子組換え）［トシリズマブ後続１］ | 3 | 1 | 1 | |
| Tocilizumab (Genetical Recombination) [Tocilizumab Biosimilar 2]トシリズマブ（遺伝子組換え）［トシリズマブ後続２］ | 3 | 1 | — | |
| Basiliximab (Genetical Recombination)バシリキシマブ（遺伝子組換え） | 2 | 1 | — | |
| Efgartigimod Alfa (Genetical Recombination) / Vorhyaluronidase Alfa (Genetical Recombination)エフガルチギモド アルファ（遺伝子組換え）・ボルヒアルロニダーゼ アルファ（遺伝子組換え） | 2 | 1 | — | |
| Interferon Alfa (NAMALWA)インターフェロンアルファ（ＮＡＭＡＬＷＡ） | 2 | 1 | — | |
| Interferon Beta-1a (Genetical Recombination)インターフェロンベータ－１ａ（遺伝子組換え） | 2 | 1 | — | |
| Interferon Gamma-1a (Genetical Recombination)インターフェロンガンマ－１ａ（遺伝子組換え） | 2 | 1 | — | |
| Nipocalimab (Genetical Recombination)ニポカリマブ（遺伝子組換え） | 2 | 1 | — | |
| Peginterferon Alfa-2a (Genetical Recombination)ペグインターフェロンアルファ－２ａ（遺伝子組換え） | 2 | 1 | — | |
| Ravulizumab (Genetical Recombination)ラブリズマブ（遺伝子組換え） | 2 | 1 | — | |
| Rozanolixizumab (Genetical Recombination)ロザノリキシズマブ（遺伝子組換え） | 2 | 1 | — | |
| Satralizumab (Genetical Recombination)サトラリズマブ（遺伝子組換え） | 2 | 1 | — | |
| Anti-human Thymocyte Immunoglobulin, Equine抗ヒト胸腺細胞ウマ免疫グロブリン | 1 | 1 | — | |
| Anti-human Thymocyte Immunoglobulin, Rabbit抗ヒト胸腺細胞ウサギ免疫グロブリン | 1 | 1 | — | |
| Crovalimab (Genetical Recombination)クロバリマブ（遺伝子組換え） | 1 | 1 | — | |
| Eculizumab (Genetical Recombination)エクリズマブ（遺伝子組換え） | 1 | 1 | — | |
| Efgartigimod Alfa (Genetical Recombination)エフガルチギモド アルファ（遺伝子組換え） | 1 | 1 | — | |
| Inebilizumab (Genetical Recombination)イネビリズマブ（遺伝子組換え） | 1 | 1 | — | |
| Interferon Beta-1b (Genetical Recombination)インターフェロンベータ－１ｂ（遺伝子組換え） | 1 | 1 | — | |
| Sutimlimab (Genetical Recombination)スチムリマブ（遺伝子組換え） | 1 | 1 | — | |
| Teceleukin (Genetical Recombination)テセロイキン（遺伝子組換え） | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).